Upcoming Trade Shows in for Science

The biotech and genetic research sector has fully blossomed into 2024 and gained unprecedented momentum. The biggest headlines in the science industry pick on innovations in biologics and rapid regulatory approvals across an expanding range of therapeutic modalities. From CRISPR-based breakthroughs to RNA therapeutics and redosable gene therapy, the science industry is undergoing a significant evolution—reshaping how we understand, develop, and deliver medical treatments. According to recent data from Nature, U.S. biologics approvals surged in 2023, outpacing the previous year across both the FDA and Center for Biologic Evaluation and Research (CBER). These approvals spanned a broad spectrum—from antibodies and proteins to gene therapies and vaccines—signaling a diversification of both treatment areas and delivery mechanisms. Notably, the FDA approved 17 biologics targeting diseases beyond oncology, venturing into respiratory, genetic, musculoskeletal, hematologic, skin, and neurological disorders. Simultaneously, CBER greenlit nearly two dozen therapies, including three RSV vaccines and a growing array of treatments for blood and infectious diseases. A key highlight of this innovation wave is the approval of the first-ever CRISPR-Cas9 gene editing therapy, CASGEVY, developed by Vertex and CRISPR Therapeutics for sickle cell disease. This groundbreaking therapy sets a new benchmark in precision medicine and gene editing. In parallel, Krystal Biotech launched the first redosable gene therapy, VYJUVEKTM, for the rare skin disorder dystrophic epidermolysis bullosa (DEB), marking another milestone in the field. This is only an example of what the future of biotechnology and genetic research could be in a few short years. Modality diversity is also accelerating. Biologics now include enzymes, fusion proteins, RNA aptamers, siRNAs, antisense oligonucleotides, bispecific antibodies, and even chemically modified proteins—offering researchers an expanded toolkit to tackle complex diseases.